GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution ... (known important human therapeutic protei...)

GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology

Date:10/24/2008

known important human therapeutic proteins. GenOdyssee's technology is protected by the international patent application PCT/EP03/13965 and is the sole property of the company.

This technology has allowed GenOdyssee to identify in the population a variety of innovative variations on existing key protein drugs such as IFN alphas and EPO and to convert such variations into novel drug candidates. The company's lead virology and immunotherapy drug candidates are GEA007.1 and GEA009.2, respectively targeted at treatments of HCV infection and cancer.

For more information about the company, please visit the company's website at http://www.genodyssee.com

About GEA007.1

GEA007.1 is a novel and first in man natural human IFN alpha protein variant identified using the company's proprietary natural evolution technology. It is found in all major human populations (Pacific, Iberian, Italian, Mexican, African, Caucasian, Chinese, Indo-Pakistan, Middle-Eastern, Japanese). GEA007.1 is a naturally occurring variant of human IFN alpha 17, which incorporates an innovative amino acid substitution G45R that provides a novel positive charge together with a change in 3-D structure of the protein receptor binding site. The biochemical and structural modifications induced in the protein binding site provide for superior anti-HCV efficacy without increased toxicity of GEA007.1 as compared to IFN alpha 2 which is the core agent of current standard of care. Long lasting second generation pegylated IFN alpha 2's have given major improvements in HCV therapy in combination with ribavirin.

GEA007.1 is particularly positioned for use in HCV genotype 1 which has become the predominant genotype worldwide and which is the most difficult to treat, as well as in patients infected with HCV genotype 3 because of the following properties:

- Stronger anti-HCV activity in fresh human hepatocytes

infect
'/>"/>

1

GOOD

Page: 1 2 3 4
Related biology technology :

1. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
2. Alfacell Receives Going Concern Audit Opinion
3. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
4. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
5. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
6. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
7. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
8. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
9. Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year
10. POET Receives Additional $76 Million in Federal Funding For Commercialization of Cellulosic Ethanol
11. Imaging Diagnostic Systems Receives its First Order for its CT Laser Mammography System for Israel

Post Your Comments:

GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution ...(known important human therapeutic protei...)